» Articles » PMID: 24051706

Neuroprotective Maraviroc Monotherapy in Simian Immunodeficiency Virus-infected Macaques: Reduced Replicating and Latent SIV in the Brain

Overview
Journal AIDS
Date 2013 Sep 21
PMID 24051706
Citations 31
Authors
Affiliations
Soon will be listed here.
Abstract

Objective: HIV-associated neurocognitive deficits remain a challenge despite suppressive combined antiretroviral therapy. Given the association between HIV-induced central nervous system (CNS) disease and replication of HIV in immune-activated macrophages, CCR5 antagonists may attenuate CNS disease by modulating inflammatory signaling and by limiting viral replication.

Design: To establish whether initiating CCR5 inhibition during early infection altered CNS disease progression, outcomes were compared between simian immunodeficiency virus (SIV)-infected macaques treated with maraviroc (MVC) versus untreated SIV-infected macaques.

Methods: Six SIV-infected rhesus macaques were treated with MVC monotherapy for 5 months beginning 24 days postinoculation; 22 SIV-infected animals served as untreated controls. SIV RNA levels in plasma, cerobrospinal fluid, and brain, and CNS expression of TNFα and CCL2 were measured by qRT-PCR. Immunostaining for CD68 and amyloid precursor protein in the brain was measured by image analysis. Plasma sCD163 was measured by ELISA.

Results: SIV RNA and proviral DNA levels in brain were markedly lower with MVC treatment, demonstrating CCR5 inhibition reduces CNS replication of SIV and may reduce the CNS latent viral reservoir. MVC treatment also lowered monocyte and macrophage activation, represented by CNS CD68 immunostaining and plasma sCD163 levels, and reduced both TNFα and CCL2 RNA expression in brain. Treatment also reduced axonal amyloid precursor protein immunostaining to levels present in uninfected animals, consistent with neuroprotection.

Conclusion: CCR5 inhibitors may prevent neurologic disorders in HIV-infected individuals by reducing inflammation and by limiting viral replication in the brain. Furthermore, CCR5 inhibitors may reduce the latent viral reservoir in the CNS. Adding CCR5 inhibitors to combined antiretroviral regimens may offer multiple neuroprotective benefits.

Citing Articles

HIV Cerebrospinal Fluid Escape: Interventions for the Management, Current Evidence and Future Perspectives.

Kelly S, Nightingale S, Gupta R, Collier D Trop Med Infect Dis. 2025; 10(2).

PMID: 39998049 PMC: 11860496. DOI: 10.3390/tropicalmed10020045.


SIV-specific antibodies protect against inflammasome-driven encephalitis in untreated macaques.

Castell N, Abreu C, Shirk E, Queen S, Mankowski J, Clements J Cell Rep. 2024; 43(10):114833.

PMID: 39383041 PMC: 11552693. DOI: 10.1016/j.celrep.2024.114833.


HIV Infection, Antiretroviral Drugs, and the Vascular Endothelium.

Kanmogne G Cells. 2024; 13(8.

PMID: 38667287 PMC: 11048826. DOI: 10.3390/cells13080672.


Changes in Cerebrospinal Fluid, Liver and Intima-media-thickness Biomarkers in Patients with HIV-associated Neurocognitive Disorders Randomized to a Less Neurotoxic Treatment Regimen.

Stroffolini G, Lazzaro A, Barco A, Pirriatore V, Vai D, Giaccone C J Neuroimmune Pharmacol. 2023; 18(4):551-562.

PMID: 37906406 PMC: 10770227. DOI: 10.1007/s11481-023-10086-7.


Downregulation of CCR5 on brain perivascular macrophages in simian immunodeficiency virus-infected rhesus macaques.

Hattler J, Irons D, Luo J, Kim W Brain Behav. 2023; 13(8):e3126.

PMID: 37366075 PMC: 10454275. DOI: 10.1002/brb3.3126.


References
1.
Vivithanaporn P, Heo G, Gamble J, Krentz H, Hoke A, Gill M . Neurologic disease burden in treated HIV/AIDS predicts survival: a population-based study. Neurology. 2010; 75(13):1150-8. PMC: 3013488. DOI: 10.1212/WNL.0b013e3181f4d5bb. View

2.
Antinori A, Arendt G, Becker J, Brew B, Byrd D, Cherner M . Updated research nosology for HIV-associated neurocognitive disorders. Neurology. 2007; 69(18):1789-99. PMC: 4472366. DOI: 10.1212/01.WNL.0000287431.88658.8b. View

3.
Clements J, Babas T, Mankowski J, Suryanarayana K, Piatak Jr M, Tarwater P . The central nervous system as a reservoir for simian immunodeficiency virus (SIV): steady-state levels of SIV DNA in brain from acute through asymptomatic infection. J Infect Dis. 2002; 186(7):905-13. DOI: 10.1086/343768. View

4.
Kelly K, Tarwater P, Karper J, Bedja D, Queen S, Tunin R . Diastolic dysfunction is associated with myocardial viral load in simian immunodeficiency virus-infected macaques. AIDS. 2012; 26(7):815-23. DOI: 10.1097/QAD.0b013e3283518f01. View

5.
Hunt P, Shulman N, Hayes T, Dahl V, Somsouk M, Funderburg N . The immunologic effects of maraviroc intensification in treated HIV-infected individuals with incomplete CD4+ T-cell recovery: a randomized trial. Blood. 2013; 121(23):4635-46. PMC: 3685899. DOI: 10.1182/blood-2012-06-436345. View